[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Genovn Therapeutics (Suzhou) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100639843",false,"NCT07621471","IL-15 Enhanced NK Cell Therapy for Solid Tumors","A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n1. Age 18-70 years;\n2. ECOG 0-1;\n3. histopathologically confirmed metastatic or recurrent solid tumors (breast, liver, lung, etc.);\n4. failed prior standard therapy;\n5. \\>=1 measurable lesion per RECIST 1.1;\n6. adequate bone marrow, liver, kidney, and coagulation function;\n7. recovered from prior treatment toxicities;\n8. signed informed consent.\n\nExclusion Criteria:\n\n1. Pregnancy\u002Flactation;\n2. other malignancy within 5 years (except cured localized tumors);\n3. active autoimmune disease or immunodeficiency;\n4. uncontrolled cardiovascular disease or infection;\n5. active TB;\n6. positive HBsAg\u002FHBcAb or HCV antibody (unless viral load undetectable);\n7. positive syphilis antibody;\n8. major surgery or vaccination within 28 days;\n9. prior cell therapy;\n10. severe allergy to study drugs;\n11. investigator judged unsuitable.","ALL","18 Years","70 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.",[26,27],"Solid Tumors","Metastatic Cancer","NOT_YET_RECRUITING","2026-05-27",{"date":31,"type":32},"2026-06-02","ACTUAL",{"date":34,"type":20},"2026-07-01",{"date":36,"type":20},"2028-12-31",{"name":38,"class":39},"Genovn Therapeutics (Suzhou) Co., Ltd.","INDUSTRY",""]